Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-k paclitaxel for the treatment of hormone receptor-positi recurrent, or metastatic breast cancer: interim analysis placebo-controlled, phase II randomised PEGGY study

Annals of Oncology

27, 2059-2066

DOI: 10.1093/annonc/mdw320

Citation Report

#	Article	IF	Citations
1	Deconvolution of Buparlisibâ€™s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Nature Communications, 2017, 8, 14683.	5.8	88
2	Targeting PIK3CA-mutant advanced breast cancer in the clinical setting. Lancet Oncology, The, 2017, 18, 842-843.	5.1	9
3	A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors. Oncologist, 2017, 22, 1491-1499.	1.9	23
4	A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or) Tj ETQq1 1 0.784314 rgBT /Ove Cancer, 2017, 86, 186-196.	1.3	28
5	Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. Cancer Treatment Reviews, 2017, 59, 93-101.	3.4	191
6	Combining â€œBottomâ€upâ€•and â€œTopâ€downâ€•Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDCâ€0941) Pharmacokinetics. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 747-755.	1.3	7
7	The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clinical Cancer Research, 2017, 23, 6580-6591.	3.2	43
8	Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer. Chinese Medical Journal, 2017, 130, 522-529.	0.9	9
9	Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?. International Journal of Molecular Sciences, 2017, 18, 85.	1.8	25
10	Targeting the PI3K pathway in cancer: are we making headway?. Nature Reviews Clinical Oncology, 2018, 15, 273-291.	12.5	762
11	Metastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management. , 2018, , 579-594.		1
12	Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis. European Journal of Cancer, 2018, 91, 38-46.	1.3	17
13	Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacological Research, 2018, 132, 47-68.	3.1	101
14	Peptide Scaffold-Based Discovery of Nonpeptide Natural Medicines to Target PI3K p85 SH2 Domain. International Journal of Peptide Research and Therapeutics, 2018, 24, 61-69.	0.9	7
15	A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Research, 2018, 20, 109.	2.2	48
16	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptorâ€“Positive Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 4380-4387.	3.2	49
17	Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast Cancer Research and Treatment, 2018, 171, 371-381.	1.1	100
18	Analytical Validation of a Hybrid Captureâ€“Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. Journal of Molecular Diagnostics, 2018, 20, 686-702.	1.2	149

#	Article	IF	Citations
19	NT21MP negatively regulates paclitaxel-resistant cells by targeting miRâ€'155â€'3p and miRâ€'155-5p via the CXCR4 pathway in breast cancer. International Journal of Oncology, 2018, 53, 1043-1054.	1.4	6
20	The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 185-197.	3.3	40
21	Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials. PLoS ONE, 2018, 13, e0192464.	1.1	51
22	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. Breast Cancer Research and Treatment, 2019, 178, 121-133.	1.1	4
23	Comparative Effectiveness of Taxaneâ€Containing Regimens for Treatment of HER2â€Negative Metastatic Breast Cancer: A Network Metaâ€analysis. Pharmacotherapy, 2019, 39, 1126-1136.	1.2	4
24	Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: A focus on breast cancer. Seminars in Cancer Biology, 2019, 59, 133-146.	4.3	48
25	BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Annals of Oncology, 2019, 30, 774-780.	0.6	57
26	PIK3CA in cancer: The past 30 years. Seminars in Cancer Biology, 2019, 59, 36-49.	4.3	122
27	Targeting PI3K in cancer: mechanisms and advances in clinical trials. Molecular Cancer, 2019, 18, 26.	7.9	940
28	Efficacy of PI3K inhibitors in advanced breast cancer. Annals of Oncology, 2019, 30, x12-x20.	0.6	145
29	Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Annals of Oncology, 2019, 30, x27-x42.	0.6	63
30	PI3K Inhibitors in Breast Cancer Therapy. Current Oncology Reports, 2019, 21, 110.	1.8	120
31	Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies. Expert Opinion on Pharmacotherapy, 2020, 21, 1915-1926.	0.9	2
32	Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094093.	1.4	55
33	Endocrine-Resistant Breast Cancer: Mechanisms and Treatment. Breast Care, 2020, 15, 347-354.	0.8	46
34	Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data . Breast Cancer: Targets and Therapy, 2020, Volume 12, 251-258.	1.0	10
35	PI3K inhibitors: review and new strategies. Chemical Science, 2020, 11, 5855-5865.	3.7	106
36	Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes. Apmis, 2020, 128, 298-307.	0.9	7

#	Article	IF	Citations
37	Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations. Future Oncology, 2021, 17, 13-36.	1.1	9
39	PIK3CA Mutation Assessment in HR+/HER2â^' Metastatic Breast Cancer: Overview for Oncology Clinical Practice. Journal of Molecular Pathology, 2021, 2, 42-54.	0.5	9
40	PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. International Journal of Molecular Sciences, 2021, 22, 3464.	1.8	119
41	Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. Cells, 2021, 10, 659.	1.8	77
42	Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Frontiers in Pharmacology, 2021, 12, 628690.	1.6	165
43	Spike-in normalization for single-cell RNA-seq reveals dynamic global transcriptional activity mediating anticancer drug response. NAR Genomics and Bioinformatics, 2021, 3, lqab054.	1.5	5
44	PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance. Critical Reviews in Oncology/Hematology, 2021, 162, 103334.	2.0	20
45	Precision medicine in breast cancer: From clinical trials to clinical practice. Cancer Treatment Reviews, 2021, 98, 102223.	3.4	34
46	Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer. Cancers, 2021, 13, 3517.	1.7	68
47	Breast Cancer Treatments: Updates and New Challenges. Journal of Personalized Medicine, 2021, 11, 808.	1.1	108
48	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-Î´ and â€“Î³. Frontiers in Immunology, 2021, 12, 718621.	2.2	16
49	Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis. BioMed Research International, 2020, 2020, 1-12.	0.9	7
50	The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis. BioMed Research International, 2020, 2020, 1-8.	0.9	8
51	Characterization of Cutaneous Adverse Events Associated With PI3K Inhibitors in 11 Patients. Journal of Immunotherapy and Precision Oncology, 2020, 3, 141-146.	0.6	1
52	TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. European Journal of Cancer, 2021, 159, 205-214.	1.3	7
53	Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia. Integrative Cancer Therapies, 2022, 21, 153473542110731.	0.8	3
54	Treatments on the Horizon: Breast Cancer Patients with Central Nervous System Metastases. Current Oncology Reports, 2022, 24, 343-350.	1.8	3
55	PIK3CAMutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. JCO Precision Oncology, 2022, 6, e2100370.	1.5	17

#	Article	IF	Citations
56	Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer. Cancer Research and Treatment, 2023, 55, 145-154.	1.3	2
57	FGFR1 is a potential therapeutic target in neuroblastoma. Cancer Cell International, 2022, 22, 174.	1.8	5
58	PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives. Cancers, 2022, 14, 2161.	1.7	15
59	Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. Exploration of Targeted Anti-tumor Therapy, 0, , 172-199.	0.5	6
60	PI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient Dermatologist. Current Dermatology Reports, 0, , .	1.1	0
61	Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions. Cancers, 2022, 14, 3774.	1.7	10
62	PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer. Cells, 2022, 11, 2508.	1.8	42
63	XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer. Biomedicine and Pharmacotherapy, 2022, 155, 113537.	2.5	9
64	PI3K Isoform Immunotherapy for Solid Tumours. Current Topics in Microbiology and Immunology, 2022, , 369-392.	0.7	1
65	Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer. JAMA Oncology, 2022, 8, 1635.	3.4	3
66	Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3KÎ±. Journal of Medicinal Chemistry, 2022, 65, 16589-16621.	2.9	23
67	PI3Kâ€“AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds. Biomolecules, 2023, 13, 93.	1.8	16
68	Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements. Cancers, 2023, 15, 1416.	1.7	7
69	The emerging role of PI3K inhibitors for solid tumour treatment and beyond. British Journal of Cancer, 2023, 128, 2150-2162.	2.9	18